Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010650 | 0.80 | HTR4 (0.41) | NCF1CXCR4HTR4 | |
| SCHEMBL5600653 | 0.77 | HTT (0.32) | HTTLMNAGAATSHRKDM4E | |
| SCHEMBL1970098 | 0.75 | PLG (0.35) | NCF1CXCR4LMNAKDM4EHTR4 | |
| SCHEMBL8276754 | 0.74 | HTR4 (0.35) | NCF1CXCR4LMNAGAATSHR | |
| SCHEMBL5114260 | 0.74 | HTR4 (0.34) | NCF1GAAHTR4 | |
| SCHEMBL15499261 | 0.72 | HTT (0.44) | HTTLMNAGAATSHRKDM4E | |
| SCHEMBL26065167 | 0.72 | HTT (0.36) | HTTLMNAGAATSHRKDM4E | |
| SCHEMBL1971581 | 0.71 | USP2 (0.35) | NCF1HTR4 | |
| SCHEMBL8276763 | 0.71 | HTR4 (0.35) | NCF1LMNAGAATSHRHTR4 | |
| SCHEMBL24837676 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273856-B2 | Linear basic compounds having NK-2 antagonist activity and formulations thereof | MENARINI RICERCHE S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| EP-1442050-B1 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI SAS (IT) | 2006-09-13 | — | — | EP | disclosed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | NCF1 1324/4885CXCR4 1959/4885HTT 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.